These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
522 related articles for article (PubMed ID: 25909818)
1. Increasing the delivery of next generation therapeutics from high throughput screening libraries. Wigglesworth MJ; Murray DC; Blackett CJ; Kossenjans M; Nissink JW Curr Opin Chem Biol; 2015 Jun; 26():104-10. PubMed ID: 25909818 [TBL] [Abstract][Full Text] [Related]
2. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads. Bergsdorf C; Ottl J Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747 [TBL] [Abstract][Full Text] [Related]
4. Fragment-based approaches in drug discovery and chemical biology. Scott DE; Coyne AG; Hudson SA; Abell C Biochemistry; 2012 Jun; 51(25):4990-5003. PubMed ID: 22697260 [TBL] [Abstract][Full Text] [Related]
5. Benefits of Strategic Small-Scale Targeted Screening. Sharlow ER Assay Drug Dev Technol; 2016 Aug; 14(6):329-32. PubMed ID: 27341343 [TBL] [Abstract][Full Text] [Related]
6. Cheminformatics approaches to analyze diversity in compound screening libraries. Akella LB; DeCaprio D Curr Opin Chem Biol; 2010 Jun; 14(3):325-30. PubMed ID: 20457001 [TBL] [Abstract][Full Text] [Related]
7. Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening. Paricharak S; Méndez-Lucio O; Chavan Ravindranath A; Bender A; IJzerman AP; van Westen GJP Brief Bioinform; 2018 Mar; 19(2):277-285. PubMed ID: 27789427 [TBL] [Abstract][Full Text] [Related]
8. Biodiversity of small molecules--a new perspective in screening set selection. Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345 [TBL] [Abstract][Full Text] [Related]
9. Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files. Bell AS; Bradley J; Everett JR; Loesel J; McLoughlin D; Mills J; Peakman MC; Sharp RE; Williams C; Zhu H Mol Divers; 2016 Nov; 20(4):789-803. PubMed ID: 27631533 [TBL] [Abstract][Full Text] [Related]
14. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case. Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858 [TBL] [Abstract][Full Text] [Related]
15. Non-stoichiometric inhibition in integrated lead finding - a literature review. Klumpp M Expert Opin Drug Discov; 2016; 11(2):149-62. PubMed ID: 26653534 [TBL] [Abstract][Full Text] [Related]
16. The European Lead Factory: An updated HTS compound library for innovative drug discovery. van Vlijmen H; Ortholand JY; Li VM; de Vlieger JSB Drug Discov Today; 2021 Oct; 26(10):2406-2413. PubMed ID: 33892142 [TBL] [Abstract][Full Text] [Related]
17. Fragment screening using X-ray crystallography. Davies TG; Tickle IJ Top Curr Chem; 2012; 317():33-59. PubMed ID: 21678136 [TBL] [Abstract][Full Text] [Related]
18. Hit finding: towards 'smarter' approaches. Langer T; Hoffmann R; Bryant S; Lesur B Curr Opin Pharmacol; 2009 Oct; 9(5):589-93. PubMed ID: 19576852 [TBL] [Abstract][Full Text] [Related]